Peter Coleman
Directeur Financier/CFO chez Cobra Biologics Holdings Ltd.
Profil
Peter Alistair Coleman is currently the Chief Executive Officer & Director at Cobra Biologics Ltd.
since 2011 and Secretary & Finance Director at Cobra Biologics Holdings Ltd.
since 2002.
He was previously the Chief Executive Officer & Director at Cobra Biologics Holding AB and the Chief Executive Officer at Roslin Cell Therapies Ltd.
from 2022 to 2023.
Postes actifs de Peter Coleman
| Sociétés | Poste | Début |
|---|---|---|
Cobra Biologics Holdings Ltd.
 Cobra Biologics Holdings Ltd. BiotechnologyHealth Technology Cobra Biomanufacturing Plc manufactures biological products for clinical studies and clients in the pharmaceutical and biotech industries. It designs and manufactures novel proteins, viruses and additional cell products. It provides DNA-based technologies, services and products. Its services include: DNA, virus and protein manufacturing, cell banking, process development, analytical services and quality assurance and regulatory support. It uses mammalian and microbial host cells for numerous therapeutic protein developments. It also provides a range of DNA maintenance technology, such as its ORT, ORT-VAC and RiboCLEAR programs. The company is headquartered in Newcastle, the United Kingdom. | Directeur Financier/CFO | 14/05/2009 |
Cobra Biologics Ltd.
 Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Cobra Biologics Ltd. engages in development of DNA-based technologies, services and products. It is a international contract development and manufacturing organization (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The company was founded in 1992 and is headquartered in Keele, the United Kingdom. | Directeur Général | 01/05/2011 |
Anciens postes connus de Peter Coleman
| Sociétés | Poste | Fin |
|---|---|---|
Roslin Cell Therapies Ltd.
 Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Directeur Général | 03/10/2023 |
Cobra Biologics Holding AB
 Cobra Biologics Holding AB Pharmaceuticals: MajorHealth Technology Cobra Biologics Holding AB manufactures biologics and pharmaceuticals for pre-clinical, clinical, and commercial products. Its services include gene therapies and vaccines, products for testing, process development and scale up of vaccine products, production of sterile drug products, and process development and production, automation, and traceability of programs. The company was founded in 2011 and is headquartered in S?dert?lje, Sweden. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Cobra Biologics Holdings Ltd.
Cobra Biologics Holdings Ltd. BiotechnologyHealth Technology Cobra Biomanufacturing Plc manufactures biological products for clinical studies and clients in the pharmaceutical and biotech industries. It designs and manufactures novel proteins, viruses and additional cell products. It provides DNA-based technologies, services and products. Its services include: DNA, virus and protein manufacturing, cell banking, process development, analytical services and quality assurance and regulatory support. It uses mammalian and microbial host cells for numerous therapeutic protein developments. It also provides a range of DNA maintenance technology, such as its ORT, ORT-VAC and RiboCLEAR programs. The company is headquartered in Newcastle, the United Kingdom. | Health Technology |
Cobra Biologics Ltd.
Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Cobra Biologics Ltd. engages in development of DNA-based technologies, services and products. It is a international contract development and manufacturing organization (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The company was founded in 1992 and is headquartered in Keele, the United Kingdom. | Health Technology |
Cobra Biologics Holding AB
Cobra Biologics Holding AB Pharmaceuticals: MajorHealth Technology Cobra Biologics Holding AB manufactures biologics and pharmaceuticals for pre-clinical, clinical, and commercial products. Its services include gene therapies and vaccines, products for testing, process development and scale up of vaccine products, production of sterile drug products, and process development and production, automation, and traceability of programs. The company was founded in 2011 and is headquartered in S?dert?lje, Sweden. | Health Technology |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Health Technology |
